Literature DB >> 24790369

MAMLD1 (CXorf6) is a New Gene for Hypospadias.

Tsutomu Ogata1, Maki Fukami1, Yuka Wada1.   

Abstract

MAMLD1 (mastermind-like domain containing 1), previously known as CXorf6 (chromosome X open reading frame 6), has been shown to be a causative gene for hypospadias. This is primarily based on the identification of nonsense mutations (E124X, Q197X, and R653X), which undergo nonsense mediated mRNA decay, in patients with penoscrotal hypospadias. Subsequent molecular studies have shown that the mouse homolog is transiently expressed in fetal Sertoli and Leydig cells around the critical period for sex development, and that transient knockdown of Mamld1 results in significantly reduced testosterone production in murine Leydig tumor cells. These findings suggest that the MAMLD1 mutations cause hypospadias primarily because of compromised testosterone production around the critical period for sex development.

Entities:  

Keywords:  CXorf6; MAMLD1; hypospadias; testosterone

Year:  2008        PMID: 24790369      PMCID: PMC4004825          DOI: 10.1297/cpe.17.87

Source DB:  PubMed          Journal:  Clin Pediatr Endocrinol        ISSN: 0918-5739


Introduction

Hypospadias is defined by the urethral opening on the ventral side of the penis, and is classified into mild glandular or penile type and severe penoscrotal or perineal type (1). It is a mild form of 46,XY disorders of sex development (DSD), and affects approximately 0.5% of male newborns (2). Hypospadias is primarily caused by compromised androgen effects, and appears as an isolated anomaly or in association with other genital anomalies such as micropenis and cryptorchidism. To date, while mutation analyses have been performed for multiple genes involved in androgen effects such as SRD5A2 for 5-alpha-redeuctase and AR for androgen receptor, pathologic mutations have been identified in only a very small portion of patients (2). This would be consistent with hypospadias being a highly heterogeneous condition subject to multiple genetic and environmental factors. We have recently shown that CXorf6 (chromosome X open reading frame 6) is a novel gene for hypospadias (3), and coined a new gene symbol MAMLD1 (mastermind-like domain containing, 1) on the basis of its characteristic protein structure with homology to mastermind like 2 (MAML2) protein (4). Herein, we review the current knowledge about MAMLD1.

Cloning of a Candidate Gene for 46,XY DSD

A gene for 46,XY DSD has been postulated around MTM1 for myotubular myopathy on Xq28, on the basis of the finding that genital development was normal in patients with intragenic MTM1 mutations, and invariably abnormal in six patients with microdeletions involving MTM1 (5,6,7,8). The six patients consisted of three sporadic and three familial cases, and five of them have glandular, penile, or penoscrotal hypospadias; the remaining one exhibits ambiguous genitalia (5,6,7). These findings suggest that a gene for 46,XY DSD, especially that for hypospadias, resides in the vicinity of MTM1, and that loss or disruption of the gene results in the development of 46,XY DSD as consequence of contiguous gene deletion syndrome. In 1997, Laporte et al. (9) identified MAMLD1 from a 430-kb region deleted in two sporadic cases with myotubular myopathy and 46,XY DSD (7). MAMLD1 comprises at least seven exons, and harbors an open reading frame on exons 3–6 that is predicted to produce two proteins of 701 and 660 amino acids as a result of in-frame alternative splicing with and without exon 4. Furthermore, subsequent studies have shown loss of MAMLD1 in all patients with myotubular myopathy and 46,XY DSD (our unpublished observation), and no other candidate gene for 46,XY DSD has been identified within the commonly deleted region. These findings imply that MAMLD1 is an excellent candidate gene for 46,XY DSD, especially hypospadias.

MAMLD1 Mutations in Hypospadiac Patients

We performed direct sequencing for the coding exons 3–6 and their flanking splice sites of MAMLD1 in 166 patients including 56 cases with hypospadias. Consequently, three nonsense mutations were identified in Japanese patients with hypospadias: E124X in maternally related half brothers from family A (cases 1 and 2), Q197X in a patient from family B (case 3), and R653X in a patient from family C (case 4) (Fig. 1) (3). The mothers of families A and C were heterozygous for the mutations, although the mother of family B was not studied.
Fig. 1.

The pedigrees and electrochromatograms of Japanese patients with nonsense mutations (A–C). The black squares indicate the patients with 46,XY DSD and the mutant MAMLD1, and the circles with dots represent molecularly confirmed carrier females. The asterisks in the chromatograms indicate the mutant and corresponding wildtype nucleotides. N.E.: not examined.

The pedigrees and electrochromatograms of Japanese patients with nonsense mutations (A–C). The black squares indicate the patients with 46,XY DSD and the mutant MAMLD1, and the circles with dots represent molecularly confirmed carrier females. The asterisks in the chromatograms indicate the mutant and corresponding wildtype nucleotides. N.E.: not examined.

Nonsense Mediated mRNA Decay (NMD)

One may argue that the hypospadias in case 4 with R653X on exon 5 is inconsistent with the apparently normal genital development in a previously reported boy with a microdeletion involving MTM1 that has resulted in generation of a fusion gene between exons 1–4 of CXorf6 and exons 3–16 of MAMLD1 (locus order: CXorf6-MTM1-MTMR1), because the coding exons 3 and 4 are preserved in both case 4 and the boy with the fusion gene (10) (Fig. 2). However, in contrast to the positive expression of the fusion gene confirmed in the biopsied muscle tissue (10), the three nonsense mutations are predicted to cause NMD because of their positions (11). Consistent with this, RT-PCR for leukocytes indicated drastically reduced transcripts in cases 1–4 (Fig. 3). Furthermore, NMD was protected by an NMD inhibitor cycloheximide, providing further support for the occurrence of NMD in the three nonsense mutations (3, 4). Thus, although NMD has not been confirmed in the testicular tissue, the results explain the apparent discordance in the genital development between case 4 and the boy described by Tsai et al. (10), and indicate that the three nonsense mutations including R653X are pathologic mutations.
Fig. 2.

Schematic representation of the R653X mutation in case 4 and the fusion gene between MAMLD1 and MTMR1. The black and the white squares in MAMLD1 indicate the translated and untranslated regions, respectively.

Fig. 3.

NMD analysis. Upper part: The black and gray boxes represent the coding regions, and the open boxes denote the untranslated regions. The positions of the mutations and variations are shown. RT-PCR for the two regions (RT-PCR-1 and -2) has produced no bands after 30 cycles and very faint bands after 40 cycles in cases 1–4. Lower part: NMD analysis in case 4 with and without an NMD inhibitor cycloheximide (CHX). After 40 cycles of RT-PCR for the region 1, no band is seen without CHX treatment, and a clear band is delineated with CHX treatment.

Schematic representation of the R653X mutation in case 4 and the fusion gene between MAMLD1 and MTMR1. The black and the white squares in MAMLD1 indicate the translated and untranslated regions, respectively. NMD analysis. Upper part: The black and gray boxes represent the coding regions, and the open boxes denote the untranslated regions. The positions of the mutations and variations are shown. RT-PCR for the two regions (RT-PCR-1 and -2) has produced no bands after 30 cycles and very faint bands after 40 cycles in cases 1–4. Lower part: NMD analysis in case 4 with and without an NMD inhibitor cycloheximide (CHX). After 40 cycles of RT-PCR for the region 1, no band is seen without CHX treatment, and a clear band is delineated with CHX treatment.

Phenotypes in Mutation Positive Patients

Cases 1–4 had penoscrotal hypospadias with chordee as the conspicuous genital phenotype, in association with other genital phenotypes (Table 1). Pituitary-gonadal serum hormone values remained within the normal range, including the human chorionic gonadotropin (hCG)-stimulated testosterone value in case 1 at two years and five mo of age, and the basal testosterone values in case 2 at one mo of age and in case 4 at three mo of age when serum testosterone is physiologically elevated. Thus, the diagnosis of idiopathic hypospadias was initially made in cases 1–4. It was suspected that testosterone production was compromised only during fetal life, or that external genitalia had defective development of anlagen or impaired responsiveness to testosterone. While placental dysfunction could also affect male genital development by attenuating the production of hCG (2), there was no pregnant episode suggestive of placental dysfunction.
Table 1.

Clinical findings of the four Japanese cases with MAMLD1 nonsense mutations

In situ Hybridization (ISH) Analysis for Mouse Mamld1

ISH analysis for mouse Mamld1 showed cell type-specific expression pattern (3). Namely, Mamld1 is specifically and transiently expressed in Sertoli and Leydig cells around the critical period for sex development (E12.5–E14.5) (Fig. 4). This expression pattern has been confirmed by double staining with antibodies for Ad4bp/Sf-1 that serves as a marker for Sertoli and Leydig cells. In extragonadal tissues at E12.5, Mamld1 expression was absent in the adrenals and weakly and diffusely identified in the external genital region including the genital tubercle at a level similar to that detected in the neighboring extragenital tissues (Fig. 2B). Mamld1 was also clearly expressed in the Müllerian ducts, forebrain, somite, neural tube, and pancreas. By contrast, Mamld1 expression was absent in the postnatal testes. These data imply that nonsense mutations of MAMLD1 cause hypospadias primarily because of transient testicular dysfunction and resultant compromised testosterone production around the critical period for sex development, and explain why postnatal endocrine data were normal in cases 1–4.
Fig. 4.

In situ hybridization analysis of the murine Mamld1. A. Expression patterns in the fetal testes at E12.5 and E14.5. The blue signals are derived from in situ hybridization for Mamld1, and the brown signals from immunohistochemical staining with Sf-1 (Ad4bp) antibodies. m: mesonephros; G: germ cell; S: Sertoli cell; and L: Leydig cell. The scale bars in the low and high power fields represent 200 µm and 20 µm, respectively. B. Expression patterns in the fetal adrenal (upper part) and external genitalia (lower part) of male mouse at E12.5. m: mesonephros; g; gonad; ad: adrenal; and GT: genital tubercle (the between two arrows). MAMLD1 is not expressed in the adrenal, and weakly and diffusely expressed in the external genitalia as in other non-genital skin tissues.

In situ hybridization analysis of the murine Mamld1. A. Expression patterns in the fetal testes at E12.5 and E14.5. The blue signals are derived from in situ hybridization for Mamld1, and the brown signals from immunohistochemical staining with Sf-1 (Ad4bp) antibodies. m: mesonephros; G: germ cell; S: Sertoli cell; and L: Leydig cell. The scale bars in the low and high power fields represent 200 µm and 20 µm, respectively. B. Expression patterns in the fetal adrenal (upper part) and external genitalia (lower part) of male mouse at E12.5. m: mesonephros; g; gonad; ad: adrenal; and GT: genital tubercle (the between two arrows). MAMLD1 is not expressed in the adrenal, and weakly and diffusely expressed in the external genitalia as in other non-genital skin tissues.

Function of Mamld1 in Testosterone Production

We performed knockdown analysis with siRNAs for Mamld1, using mouse Leydig tumor (MLT) cells that retain the capability of testosterone production and the responsiveness to hCG stimulation (4). When the mRNA level of endogenous Mamld1 was severely reduced in the mouse Leydig tumor cells (25–30%), testosterone production was decreased to 50–60% of the previous level after 48 h of incubation and one h after hCG stimulation. This implies that MAMLD1 is involved in the testosterone biosynthesis. Furthermore, since testosterone production would probably be attenuated rather than abolished in the absence of MAMLD1, this is consistent with the hypospadias phenotype in the affected patients (2).

Conclusions

MAMLD1 is a causative gene for hypospadias, and possibly other forms of 46,XY DSD. It appears to play a supportive role in the testosterone production around the critical period for sex development. Further studies including knockout mouse experiments will permit to clarify MAMLD1 dependent molecular network involved in testosterone production.
  10 in total

Review 1.  Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges.

Authors:  Holly A Kuzmiak; Lynne E Maquat
Journal:  Trends Mol Med       Date:  2006-06-16       Impact factor: 11.951

2.  CXorf6 is a causative gene for hypospadias.

Authors:  Maki Fukami; Yuka Wada; Kanako Miyabayashi; Ichizo Nishino; Tomonobu Hasegawa; Agneta Nordenskjöld; Giovanna Camerino; Christine Kretz; Anna Buj-Bello; Jocelyn Laporte; Gen Yamada; Ken-Ichirou Morohashi; Tsutomu Ogata
Journal:  Nat Genet       Date:  2006-11-05       Impact factor: 38.330

3.  Mutations in the MTM1 gene implicated in X-linked myotubular myopathy. ENMC International Consortium on Myotubular Myopathy. European Neuro-Muscular Center.

Authors:  J Laporte; C Guiraud-Chaumeil; M C Vincent; J L Mandel; S M Tanner; S Liechti-Gallati; C Wallgren-Pettersson; N Dahl; W Kress; P A Bolhuis; M Fardeau; F Samson; E Bertini
Journal:  Hum Mol Genet       Date:  1997-09       Impact factor: 6.150

4.  Characterization of MTM1 mutations in 31 Japanese families with myotubular myopathy, including a patient carrying 240 kb deletion in Xq28 without male hypogenitalism.

Authors:  Tzung-Chang Tsai; Hideo Horinouchi; Satoru Noguchi; Narihiro Minami; Kumiko Murayama; Yukiko K Hayashi; Ikuya Nonaka; Ichizo Nishino
Journal:  Neuromuscul Disord       Date:  2005-01-28       Impact factor: 4.296

5.  The novel contiguous gene syndrome of myotubular myopathy (MTM1), male hypogenitalism and deletion in Xq28:report of the first familial case.

Authors:  O Bartsch; W Kress; A Wagner; E Seemanova
Journal:  Cytogenet Cell Genet       Date:  1999

6.  Cloning and characterization of an alternatively spliced gene in proximal Xq28 deleted in two patients with intersexual genitalia and myotubular myopathy.

Authors:  J Laporte; P Kioschis; L J Hu; C Kretz; B Carlsson; A Poustka; J L Mandel; N Dahl
Journal:  Genomics       Date:  1997-05-01       Impact factor: 5.736

7.  Mastermind-like domain-containing 1 (MAMLD1 or CXorf6) transactivates the Hes3 promoter, augments testosterone production, and contains the SF1 target sequence.

Authors:  Maki Fukami; Yuka Wada; Michiyo Okada; Fumiko Kato; Noriyuki Katsumata; Takashi Baba; Ken-ichirou Morohashi; Jocelyn Laporte; Motoo Kitagawa; Tsutomu Ogata
Journal:  J Biol Chem       Date:  2007-12-27       Impact factor: 5.157

8.  Deletions in Xq28 in two boys with myotubular myopathy and abnormal genital development define a new contiguous gene syndrome in a 430 kb region.

Authors:  L J Hu; J Laporte; W Kress; P Kioschis; R Siebenhaar; A Poustka; M Fardeau; A Metzenberg; E A Janssen; N Thomas; J L Mandel; N Dahl
Journal:  Hum Mol Genet       Date:  1996-01       Impact factor: 6.150

Review 9.  Hypospadias: anatomy, etiology, and technique.

Authors:  Laurence S Baskin; Michele B Ebbers
Journal:  J Pediatr Surg       Date:  2006-03       Impact factor: 2.545

10.  Characterisation of mutations in 77 patients with X-linked myotubular myopathy, including a family with a very mild phenotype.

Authors:  Valérie Biancalana; Olivier Caron; Sabina Gallati; Frank Baas; Wolfram Kress; Giuseppe Novelli; Maria Rosaria D'Apice; Clotilde Lagier-Tourenne; Anna Buj-Bello; Norma B Romero; Jean-Louis Mandel
Journal:  Hum Genet       Date:  2002-11-28       Impact factor: 4.132

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.